Advertisement
Advertisement
U.S. markets open in 2 hours 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
397.97+20.25 (+5.36%)
At close: 04:00PM EST
403.14 +5.17 (+1.30%)
Pre-Market: 06:34AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close377.72
Open399.83
Bid0.00 x 1100
Ask0.00 x 800
Day's Range392.93 - 403.54
52 Week Range249.50 - 403.77
Volume623,899
Avg. Volume245,249
Market Cap22.503B
Beta (5Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • argenx SE
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • Benzinga

    Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review

    The FDA has accepted Argenx SE's (NASDAQ: ARGX) Biologics License Application for subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). Under the Priority Review status, the FDA has granted a Prescription Drug User Fee Act (PDUFA) target action date of March 20, 2023. SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's (NASDAQ: HALO) Enhanze drug delivery technology that facilitates the SC administration of biologics

  • Insider Monkey

    Should You Invest in argenx SE (ARGX)?

    Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […]

  • Insider Monkey

    Will argenx SE (ARGX) Deliver Solid Performance in Near-Term?

    Baron Funds, an investment management company, released its “Baron Opportunity Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 2.38% (Institutional Shares) compared to a 3.37% decline for the Russell 3000 Growth Index and a 4.88% decline for the S&P 500 Index. The […]

Advertisement
Advertisement